Structural Heart Devices Market Outlook, Competitive Insights, and Growth Factors during the Forecast Period 2022-2028
Structural Heart Devices Market |
Congenital (present at birth)
cardiac anomalies are referred to as structural heart illnesses, along with
abnormalities that develop in the heart's valves and arteries as a result of
disease-related wear and tear. A non-coronary disorder of the heart, structural
heart disease has no effect on the heart's blood arteries. Atrial septal
defect, patent foramen oval, ventricular septal defect, paravalvular leak,
arterial/venous fistulae, and congenital heart disease are among the most
common structural heart conditions.
Due to ongoing efforts to develop
novel products and subsequent product releases by major key players based in
the area, North America is anticipated to have a prominent position in the
global Structural
Heart Devices Market. For instance, the American company Edwards
Lifesciences Corporation is concentrating on the launch of the SAPIEN 3 Ultra
and CENTERA Valves in 2017. The SAPIEN 3 Ultra system is a cutting-edge
platform with an on-balloon delivery design and extensible Axela sheath
technology. This innovative invention should speed up the manufacturing
processes while reducing error-proneness.
Additionally, because to the
rising incidence of valvular heart disease (VHD) throughout the continent,
structural heart devices are predicted to experience significant increase in
Europe. Incidence of VHD was 63.9 per 100 000 person-years, with aortic
stenosis (AS) accounting for 47.2% of cases, mitral regurgitation (MR) for
24.2%, and aortic regurgitation (AR) for 18.0%, according to a study published
in the British Medical Journal (BMJ) in 2017. To arrive at this result, the
study examined hospital data collected nationally between 2003 and 2010.
Modern items, such sutureless
heart valves, are substantially more expensive than earlier models. For
instance, LivaNova, Plcsuture-free .'s aortic heart valve costs more than US$
9,000, but tissue heart valves made by Medtronic Plc. and Abbott Laboratories cost
about US$ 5,000 in the United States. The use of sutureless technology has been
constrained by its nearly twofold price, which is also slowing the Structural Heart Devices Market expansion.
Key players in Global Structural Heart Devices Market include Abbott
Laboratories, Medtronic Plc., Edwards Lifesciences Corporation, Boston
Scientific Corporation, CryoLife Inc., LivaNova Plc., Cook Group Incorporated,
Endologix Inc., and W. L. Gore & Associates, Inc.
Comments
Post a Comment